BeOne Medicines AG (ONC) Stock Price & News

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market. BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia

About BeOne Medicines AG

CEOJohn Vincent Oyler | John Vincent Oyler

Employees12K

FoundedOct 28, 2010

Headquarters-

SectorHealth Care

IndustryBiotechnology

Websitebeonemedicines.com

Analyst	Recommendation	Action	Price target	Projected	Date
Jill Wu CMB International Securities	Buy	Maintained	$468.62	+14.5%	11/06/2026
Unknown Analyst Goldman Sachs	Buy	Maintained	$500.84	+22.4%	11/06/2026
Leonid Timashev RBC Capital	Buy	Reiterated	$465.00	+13.6%	11/05/2026
Michael Schmidt Guggenheim	Buy	Maintained	$430.00	+5.1%	11/05/2026
Yaron Werber TD Cowen	Buy	Maintained	$477.00	+16.6%	11/06/2026
Yanan Zhu Wells Fargo	Buy	Reiterated	$435.00	+6.3%	11/06/2026
Sean Laaman Morgan Stanley	Buy	Maintained	$465.00	+13.6%	11/06/2026
Gregory Renza Truist Financial	Buy	Reiterated	$448.00	+9.5%	11/06/2026
Reni Benjamin Citizens JMP	Buy	Maintained	$463.00	+13.1%	11/06/2026
Etzer Darout Barclays	Buy	Maintained	$446.00	+9%	11/06/2026
Yigal Nochomovitz Citi	Buy	Maintained	$466.00	+13.9%	10/19/2026
Derek Archila Wells Fargo	Buy	Maintained	$400.00	-2.3%	10/16/2026
Jessica Fye J.P. Morgan	Buy	Maintained	$445.00	+8.7%	10/01/2026
Kalpit Patel Wolfe Research	Buy	Reiterated	$370.00	-9.6%	08/09/2026
David Li Bank of America Securities	Buy	Reiterated	$423.00	+3.4%	08/06/2026
Faisal Khurshid Jefferies	Buy	Upgraded	$380.00	-7.1%	07/12/2026
Unknown Analyst J.P. Morgan	Buy	Maintained	$415.00	+1.4%	05/20/2026
Unknown Analyst Leerink Partners	Buy	Maintained	$367.00	-10.3%	05/15/2026
Rebecca Liang Bernstein	Buy	Maintained	$412.00	+0.7%	03/18/2026

All values in USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	1.41B	1.50B	1.51B	1.71B
Cost of goods sold	196.51M	142.42M	167.22M	174.53M
Cost of revenue	196.51M	142.42M	167.22M	174.53M
Research and development expenses	523.66M	615.42M	541.22M	612.28M
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	529.00M	555.29M	555.10M	593.21M
Operating expense	1.05B	1.17B	1.10B	1.21B
Total operating expenses	1.25B	1.31B	1.26B	1.38B
Operating income	163.11M	185.04M	249.90M	325.05M
Other non operating income	-4.76M	4.16M	14.54M	-2.68M
EBT including unusual items	147.16M	149.24M	259.22M	312.46M
EBT excluding unusual items	160.80M	189.96M	259.22M	309.33M
Income tax expense	22.32M	82.74M	31.86M	75.45M
Effective tax rate	15.17%	55.44%	12.29%	24.15%
Other operating expenses	-	-	-	-
Net income	124.84M	66.50M	227.36M	237.01M
Net profit margin	8.84%	4.44%	15.02%	13.90%
Earnings per share	1.09	0.58	1.96	2.05
Interest and investment income	13.79M	32.37M	27.66M	27.90M
Interest expense	-10.76M	-32.47M	-32.89M	-39.74M
Net interest expenses	3.03M	-103.00K	-5.22M	-11.84M
Depreciation and amortization charges	-	-	-	-
EBITDA	198.86M	219.47M	289.30M	363.97M
Gain or loss from assets sale	-	-	-	-

Ask anything